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Abstract
Background: SARS-CoV-2 is frequently shed in the stool of patients hospitalised with COVID-19. The extent of
faecal shedding of SARS-CoV-2 among individuals in the community, and its potential to contribute to spread of
disease, is unknown.
Methods: In this prospective, observational cohort study among households in Liverpool, UK, participants
underwent weekly nasal/throat swabbing to detect SARS-CoV-2 virus, over a 12-week period from enrolment
starting July 2020. Participants that tested positive for SARS-CoV-2 were asked to provide a stool sample three and
14 days later. In addition, in October and November 2020, during a period of high community transmission, stool
sampling was undertaken to determine the prevalence of SARS-CoV-2 faecal shedding among all study participants.
SARS-CoV-2 RNA was detected using Real-Time PCR.
Results: A total of 434 participants from 176 households were enrolled. Eighteen participants (4.2%: 95%
confidence interval [CI] 2.5–6.5%) tested positive for SARS-CoV-2 virus on nasal/throat swabs and of these, 3/17
(18%: 95% CI 4–43%) had SARS-CoV-2 detected in stool. Two of three participants demonstrated ongoing faecal
shedding of SARS-CoV-2, without gastrointestinal symptoms, after testing negative for SARS-CoV-2 in respiratory
samples. Among 165/434 participants without SARS-CoV-2 infection and who took part in the prevalence study,
none had SARS-CoV-2 in stool. There was no demonstrable household transmission of SARS-CoV-2 among
households containing a participant with faecal shedding.
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Conclusions: Faecal shedding of SARS-CoV-2 occurred among community participants with confirmed SARS-CoV-2
infection. However, during a period of high community transmission, faecal shedding of SARS-CoV-2 was not
detected among participants without SARS-CoV-2 infection. It is unlikely that the faecal-oral route plays a significant
role in household and community transmission of SARS-CoV-2.
Keywords: SARS-CoV-2, COVID-19, Cohort study, Faecal shedding, Transmission, Community, Asymptomatic,
Gastrointestinal
Background
On January 30th 2020 the World Health Organisation
(WHO) declared a public health emergency of inter-
national concern with regards to the spread of the novel
virus severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), which cause COVID-19 [1].COVID-19 is
a multisystem disease with the most commonly reported
symptoms comprising fatigue, non-productive cough,
dyspnoea and myalgia [2, 3]. Patients may also present
with gastrointestinal symptoms including abdominal
pain, diarrhoea, anorexia, nausea and vomiting [2–4].
Epidemiological studies have shown that transmission
occurs mostly by respiratory droplets, but also via fomi-
tes and possibly via aerosols [3, 5]. However, there is in-
creasing evidence to suggest that the faecal-oral route
could also play a role in the transmission of SARS-CoV-
2. Zhang et al. first isolated live SARS-CoV-2 virus from
faecal samples; following inoculation of the stool suspen-
sion into Vero cells, the virus was observed under elec-
tron microscopy [6]. The presence of live virus in faecal
specimens of SARS-CoV-2 infected patients has subse-
quently been confirmed in several studies, including
from patients without gastrointestinal symptoms [7–9].
Studies in hospitalised patients have reported SARS-
CoV-2 faecal shedding in up to 50% of cases [10]. A re-
cent systematic review investigated the presence of viral
RNA either in the faeces or in the intestinal cells of pa-
tients with a confirmed diagnosis of COVID-19 [11].
The systematic review included 27 studies, evaluating a
total of 671 patients with laboratory-confirmed COVID-
19, of whom 312 (46.5%) had a positive stool sample for
viral RNA [11].
There are no published studies investigating faecal
shedding in an asymptomatic or pauci-symptomatic
community-based population. We have conducted a
community household cohort study in Liverpool City
Region, UK since July 2020, known as the COVID-LIV
Study [12]. The incidence of SARS-CoV2 infection in
Liverpool reached a weekly rate of 659 per 100,000
population in early-mid October 2020, with a positivity
rate of 18.1% [13]. This provided an opportunity to in-
vestigate faecal shedding of SARS-CoV2 in a high inci-
dence community setting, prior to vaccine introduction
in order to better understand the role of faecal-oral
transmission in disease spread, to subsequently inform
the implementation of appropriate public health mea-
sures. We obtained serial stool samples from respiratory
positive SARS-CoV-2 cases and undertook a two-point




The COVID-LIV Study is an observational cohort study
recruiting households in the Liverpool City Region to in-
vestigate household transmission of SARS-CoV-2. Selec-
tion and recruitment of participants, along with detailed
study methodology, has been described previously [12].
Briefly, participants were recruited from an established
household health survey undertaken by the NIHR Col-
laboration for Leadership in Applied Health Research
and Care (CLAHRC, now Applied Research Collabor-
ation, ARC) and through GP surgeries and local media
advertisements [14]. Enrolment of households began in
July 2020; participants underwent baseline and three-
monthly follow-up serological and immunological inves-
tigations, together with a weekly combined self-
administered nasal/throat swab for SARS-CoV-2, for a
total of 12 weeks from enrolment. All participants were
invited to complete a weekly electronic questionnaire
detailing their social interactions and the presence of
any symptoms of illness (Additional file 1).
Stool sampling
Participants that tested positive for SARS-CoV-2 on
combined nasal/throat swabs were asked to provide a
stool sample within approximately 3 days of the positive
test result and 14 days later. In mid-October 2020 all
households were invited by email to undertake optional
stool sampling at two time points, once in October 2020
and once in November 2020. Those participants who in-
dicated via email that they would be willing to provide a
stool sample were provided with stool sampling kits. A
courier picked up the stool samples within 24 h of the
stool sample being taken and returned them to the la-
boratory at the University of Liverpool. Upon receipt,
the stool samples were stored at − 80 °C.
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Laboratory testing
Nasal/throat swabs
Nasal/throat swabs were collected using eswab (Copan
Diagnostics, USA) and stored at 4 °C overnight. SARS-
CoV-2 RNA was extracted using the Quick-DNA/RNA
Viral MagBead extraction kit (Zymo Research Corp.
USA).
Stool samples
The samples were thawed and approximately 200–400
mg of faecal material was resuspended in 1.60 ml phos-
phate buffered saline (PBS) and stored at − 80 °C until
RNA extraction was undertaken. Following thawing, the
faecal suspensions were vortexed for 30 s and 300 μl was
mixed 1:1 with 300 ul DNA/RNA Shield (Zymo Re-
search Corp. USA). Samples were centrifuged at 5000
rpm for 3 min to pellet debris and 400ul of the super-
natant was taken for RNA extraction, using the Quick-
DNA/RNA Viral MagBead extraction kit (Zymo Re-
search Corp. USA).
SARS-CoV-2 RNA detection
SARS-CoV-2 RNA was detected using the Genesig®
Real-Time PCR COVID-19 (CE) assay (Primerdesign
Ltd., UK), which targets the orf1 ab genome region, on a
Rotor-Gene Q (Qiagen, Germany). The internal extrac-
tion control (IEC) template from the Genesig® Real-
Time PCR kit (Primerdesign Ltd., UK) was added to
each sample prior to extraction according to manufac-
turer’s instructions, and detected using RT-PCR. If the
IEC failed the sample was re-extracted and again tested
by RT-PCR. Each RT-PCR run also included a positive
template control from the Genesig® Real-Time PCR kit
(Primerdesign Ltd., UK). Samples with a cycle threshold
(Ct) value of below 37 were considered positive. Samples
with a Ct value between 37 and 40 were considered in-
determinate and were retested in triplicate; samples were
considered positive if two out of three replicates had a
Ct value below 40.
Participant variables
Participants provided demographic details, including
date of birth, sex and postcode of residence. Postcode of
residence was used to assign socio-economic status
using English Index of Multiple Deprivation (IMD). For
participants who tested positive for SARS-CoV-2 on
nasal/throat swab, self-reported clinical data were ob-
tained including symptoms at the time of positive test,
medications and presence of co-morbidities.
Data analysis
Characteristics of the study cohort who provided a stool
sample were compared with those that did not, by using
a χ2 test or Fisher’s exact test for categorical variables
and Wilcoxon rank sum test for continuous variables.
Exact binomial 95% confidence intervals (CIs) for pro-
portions were calculated for SARS-CoV-2 positive par-
ticipants. All analyses were conducted using R version
4.0.3 (R Core Team, Vienna, Austria).
Results
Study population
A total of 176 households including 434 participants
were enrolled in the COVID-LIV Study between 9th July
and 30th September 2020. Median age of participants
was 46.0 (IQR: 24.3–63.0) and 53.7% (222/434) identified
as female. Of the 176 enrolled households, 17.6% (31/
176) were one person households, 46% (81/176) were
two person households, 14.8% (26/176) were three per-
son households and 21.6% (38/176) four of more person
households. Among enrolled participants, 18/434 (4.2%:
95% CI 2.5–6.5) tested positive for SARS-CoV-2 on
nasal/throat swab during the 12 week active follow-up
period. Of these 18 SARS-CoV-2 positive cases, two
were from the same household but tested positive > 6
weeks apart, 55.6% (10/18) were female and the median
age was 42 years (range 10–72 years); 17 provided at
least one stool sample (Fig. 1). Among 40% (165/416) of
SARS-CoV-2 nasal/throat swab negative participants
who provided a stool sample within the two-point preva-
lence sampling, 53.9% (89/165) were female and the me-
dian age was 58 years (range 1–86 years). Participants
that took part in the prevalence stool sampling were
more likely to be older (p < 0.001) and from less socio-
economically deprived IMD deciles (p < 0.001) than
those that did not take part (Table 1) There was no dif-
ference in sex between the two groups of participants
(p = 0.912; Table 1). A total of 153 participants provided
a sample during the October 2020 sampling period and
135 in the November 2020 sampling period; 123 partici-
pants provided stools samples at both time points (Fig.
1).
SARS-CoV-2 nasal/throat swab PCR positive participants
All PCR positive cases occurred between August and
October 2020, with the majority (77.8%; 14/18) of the
cases occurring before the peak of SARS-CoV-2 infec-
tion in the Liverpool City Region (Fig. 2). Five of the
cases (27.8%) tested positive for SARS-CoV-2 on two or
more consecutive nasal/throat swabs. Cases were from a
variety of household sizes ranging from one to four oc-
cupants. Six cases (33.3%) were asymptomatic and three
cases (16.7%) reported gastrointestinal symptoms includ-
ing diarrhoea, nausea and vomiting. None of the cases
was hospitalised in the 2 weeks following the first nasal/
throat swab positive result. All cases reported no co-
morbidities.
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SARS-CoV-2 faecal shedding among nasal/throat swab PCR
positive participants
Three of the 17 participants who provided a stool sam-
ple had SARS-CoV-2 RNA detected (18%: 95% CI 4–
43%). The three participants with faecal shedding
included a male aged 15–19 years (four person house-
hold; two household members aged 50–54 years and one
aged 15–19 years), a female aged 15–19 years (two per-
son household; other household member aged 55–59
years) and 50–54 year old male (three person household;
Fig. 1 Stool samples and SARS-CoV-2 PCR test results among COVID-LIV participants. (123 participants took part in the stool sampling at both
time points)
Table 1 Characteristics of COVID-LIV participants




No stool provided Stool provided Overall P value
(N = 251) (N = 165) (N = 416) (N = 18)
IMD < 0.001
1 (most deprived) 70 (27.9%) 25 (15.2%) 95 (22.8%) 5 (27.8%)
2 32 (12.7%) 15 (9.1%) 47 (11.3%) 3 (16.7%)
3 15 (6.0%) 14 (8.5%) 29 (7.0%) < 3
4 30 (12.0%) 16 (9.7%) 46 (11.1%) < 3
5 22 (8.8%) 15 (9.1%) 37 (8.9%) < 3
6 24 (9.6%) 25 (15.2%) 49 (11.8%) < 3
7 12 (4.8%) 15 (9.1%) 27 (6.5%) < 3
8 18 (7.2%) 23 (13.9%) 41 (9.9%) < 3
9 17 (6.8%) 3 (1.8%) 20 (4.8%) < 3
10 (least deprived) 11 (4.4%) 14 (8.5%) 25 (6.0%) < 3
Age
Median IQR [Min, Max] 15/39/57 [1, 82] 42/58/66 [1, 86] 24/46/63 [1, 86] < 0.001 26/42/61 [10, 72]
Sex
Female 134 (53.4%) 89 (53.9%) 223 (53.6%) 0.912 10 (55.6%)
Male 117 (46.6%) 76 (46.1%) 193 (46.4%) 8 (44.4%)
The P value compares those who provided a stool sample and those who did not in the SARS-CoV-2 nasal/throat swab negative population
IMD refers to the English Index of Multiple Deprivation deciles, assigned based on patient postcode
IQR refers to the interquartile range
< 3 refers to numbers suppressed to prevent participant disclosure
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Fig. 2 Background rate of SARS-CoV-2 cases in the Liverpool City Region in relation to the timing of COVID-LIV cases, stool sampling and public
health measures. (SARS-CoV-2 case data for the Liverpool City Region adapted from https://coronavirus.data.gov.uk/details/download
[accessed 09/12/2020])


















a-002 1 35.00 7 5, 49, 78 Negative N/A
b-001 1 35.49 15 8, 23, 71, 86 Negative N/A
c-002 1 35.69 14 6, 21, 69, 98 Negative N/A
d-002 1, 6 33.87, 35.11 15 8, 16 8, 16 20.00, 33.03
e-002 1 35.28 6 7,20 Negative N/A
f-001 1 35.01 7 8, 18 Negative N/A
g-001 1 34.41 7 6, 20, 28 Negative N/A
h-003 1, 5, 7 22.13, 32.65, 28.05 14 6 Negative N/A
i-002 1 36.79 6 7, 15 Negative N/A
j-001 1 35.60 7 4, 15 Negative N/A
k-002 1 27.07 6 6, 18 Negative N/A
l-002 1 36 12 6, 13, 23 Negative N/A
m-003 1, 8, 14 32.90, 28.52, 34.07 21 6, 19 Negative N/A
n-003 1 30.78 6 6, 17, 34, 61 Negative N/A
o-003 1, 7 16.40, 35.48 14 21 21 23.66
p-002 1, 7 19.18,33.14 NA 4 4 33.46
q-001 1 30.62 6 7, 14 Negative N/A
r-003 1 31.70 6 NA N/A N/A
aRandom anonymous ID
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other household members aged 50–54 years and 20–24
years); none reported gastrointestinal symptoms. None
of the three faecal shedders took any regular medica-
tions. The Ct values for the stool samples ranged from
20.00–33.46; of the three participants who faecally shed
viral RNA, two had among the lowest Ct values (highest
viral load) on the nasal/throat swabs (16.40 and 19.18),
and one participant tested positive on repeat nasal/
throat swabbing (Table 2). Two out of the three partici-
pants had detectable virus in stool beyond the time that
respiratory samples tested negative for viral RNA
(Table 2). One participant tested positive for viral RNA
in the stool at 16 days, and the other participant at 21
days after a nasal/throat swab positive test for SARS-
CoV-2 virus; they continued to shed in their stools for
three and 7 days respectively after testing PCR negative
on nasal/ throat swab. There was no transmission within
the households of those who tested positive for viral
RNA in stool.
Faecal shedding of SARS-CoV-2 among nasal/throat swab
PCR negative participants
None of the 165 participants that tested negative for
SARS-CoV-2 RNA in the upper respiratory tract had
viral RNA detected in their stool samples in either Octo-
ber or November 2020.
Discussion
To our knowledge this is the first reported community-
based study investigating faecal shedding of SARS-CoV-
2. The overall rate of faecal shedding in this community
was low; while 3/17 participants who tested positive for
SARS-CoV-2 on nasal/throat swab showed evidence of
faecal shedding, 0/165 participants that were negative
for SARS-CoV-2 on nasal/throat showed evidence of
viral RNA in their stools when sampled over two time
points.
In comparison to the relatively low rate of faecal shed-
ding among respiratory PCR positive subjects reported
here, studies conducted in hospital settings have re-
ported faecal shedding in up to 50% of patients with
COVID-19 [10]. This could potentially be due to differ-
ences in the severity of symptoms, viral load in the re-
spiratory tract, or in the propensity of the virus to
disseminate, which post-mortem evidence suggests hap-
pens in patients who have died from severe COVID-19
[15]. However, our study showed that participants with
both high and low Ct values in respiratory material shed
the virus faecally. Moreover, a recent study showed no
difference in the duration of viral shedding, or in SARS-
CoV-2 load, in stool samples among patients with mild
or severe disease [16]. This highlights that other factors
other than viral load are likely to be involved in the fae-
cal shedding of SARS-CoV-2.
Faecal shedding in this study was not associated with
the presence of gastrointestinal symptoms. Previous
studies of faecal shedding in patients who were asymp-
tomatic or had mild symptoms of SARS-CoV-2 infection
also demonstrated a lack of association between faecal
shedding and gastrointestinal symptoms [4, 17–20].
However, several hospital-based studies found that
gastrointestinal symptoms, in particular diarrhoea, were
associated with faecal shedding [21–23]. Moreover, those
with gastrointestinal symptoms had a longer duration
between symptom onset and viral clearance [21]. A re-
cent study investigated the intestinal microbiota in
SARS-CoV-2 hospitalised patients with GI manifesta-
tions. This study found that patients with prolonged GI
manifestations had a reduction in the diversity and rich-
ness in their microbiota and prolonged viral clearance
[24]. Studies report that the relative abundance of the
microbiota Coprobacillus, Clostridium ramosum, and
Clostridium hathewayi positively correlated to COVID-
19 severity [25]. Furthermore, studies have shown that
ACE-2 receptor is the entry point for SARS-CoV-2 virus
into the gastrointestinal tract [26]. The interaction be-
tween the ACE-2 receptor and SARS-CoV-2 can lead to
receptor dysregulation, intestinal inflammation and the
manifestation of gastrointestinal symptoms [25]. Differ-
ences in the expression of the ACE-2 receptor in the
gastrointestinal tract could explain differences in faecal
shedding and gastrointestinal symptoms among individ-
uals with SARS-CoV-2 infection.
Two out of three participants that had viral RNA de-
tected in their stools demonstrated persistent faecal
shedding despite negative nasal/throat swabs for SARS-
CoV-2. Previous studies in hospitalised patients have
demonstrated prolonged faecal shedding for up to 5
weeks after respiratory samples were negative for viral
RNA, including one study which showed that 80% of
children had persistent positive real time RT- PCR test
of rectal swabs [19, 27, 28].
Persistent faecal shedding of SARS-CoV-2 may poten-
tially allow faecal-oral transmission. However, within our
study there was no transmission of infection within the
households of participants who had detectable viral RNA in
their stools. Furthermore, in the two-point prevalence stool
sampling none of the participants had detectable SARS-
CoV-2 RNA in stool, despite sampling being undertaken
during a period of high transmission of SARS-CoV-2 in the
community. Together, our data do not suggest a significant
role for faecal-oral transmission in the community. Add-
itionally, our findings have implications for the utility of
rectal swabs for COVID-19 diagnosis and public health sur-
veillance, and for the use of wastewater for surveillance of
SARS-CoV-2 [8, 29]. A number of the participants, particu-
larly those younger and from more socioeconomically de-
prived neighbourhoods, did not provide faecal samples.
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This further suggests that the use of rectal swabs could pro-
duce partial, and systematically biased data.
Limitations
Participant engagement in the two-point prevalence
stool sampling was low. Only 40% (165/416) of enrolled,
respiratory PCR negative participants provided a stool
sample; participants providing a stool sample were
slightly older and less deprived than the remainder of
the COVID-LIV population. This highlights the difficulty
of undertaking stool surveillance in the community, even
among our research-engaged study population. Add-
itionally, as faecal shedding appears more common in
children compared with adults, we may have underesti-
mated shedding in the respiratory negative participants
[27, 28]. We also did not obtain enough serial stool sam-
ples to determine cessation of faecal shedding. Further-
more, for mucosal pathogens such as SARS-CoV-2,
relating PCR detection of viral nucleic acid in clinical
samples to infectiousness remains problematic. Finally,
during the study period there were few strains of the
SARS-CoV-2 virus in circulation. Since December 2020,
there has been an increase in the alpha (B.1.1.7; first de-
tected in the UK) variant in the UK which has spread
globally and from May 2021 the delta (B.1.617.2; first de-
tected in India) variant [30, 31]. As new strains emerge
it is important to investigate the propensity of these new
variants to be associated with faecal shedding, and the
consequent role of faecal-oral transmission in virus
spread.
Conclusion
In this community household cohort study, faecal shed-
ding of SARS-CoV-2 viral RNA was detected among re-
spiratory positive participants. However, in two-point
prevalence stool sampling conducted during an intense
period of community transmission, we did not detect
SARS-CoV-2 viral RNA in the stool of SARS-CoV-2 re-
spiratory negative participants. Our study demonstrates
that faecal shedding of SARS-CoV-2 is unlikely to play a
significant role in transmission of infection in house-
holds and in the community.
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